A Phase 4 interventional study of Ferric Carboxymaltose (FCM) and Ferrous Sulfate in Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease, Iron Deficiency Anaemia Due to Dietary Causes and Iron Deficiency Anemia Treatment, sponsored by Children's Hospital of Orange County. Not yet recruiting. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2026-02-17.
Sponsored by Children's Hospital of Orange County · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency — 7 open to participants now, 7 under way, none of them phase 3. ferric carboxymaltose · Anemia, Iron-Deficiency.
Among the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, this one is the 22nd largest by planned enrollment, is one of 4 that started in 2026, is one of 24 in phase 4, and was the 54th registered.
602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.
Browse Anemia, Iron-Deficiency studies →7 of the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency are open now, in 1 country. Recruiting first, the newest first:
Western Galilee Hospital-Nahariya · Sites in Israel
Ages 18–50 · Women only
Hawler Medical University
Ages 18–45 · Women only
Zhaojian Niu,MD
Ages 18–75
Liverpool Hope University
Ages 60–85
Hospital de Santa Cruz, Portugal
Ages 18–99
By country, each count listing its studies:
ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →
Of the 53 Anemia, Iron-Deficiency studies recruiting now, 19 (36%) set no upper age limit and 30 (57%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 1 Year to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 17 · Phase 4 24
First in 2006; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 100 across 461 interventional studies indexed under Anemia, Iron-Deficiency.
Median enrollment 100 across the 57 interventional studies. Of the 45 that completed or were terminated, 15 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 57 have an industry lead sponsor. The 10 most frequent:
Children's Hospital of Orange County is the lead sponsor of 19 studies on the registry; 11 are open to participants now.
Children's Hospital of Orange County has 1 study filed under Anemia, Iron-Deficiency — fewer than ten, so there is no comparison to draw.
2 of the studies testing ferric carboxymaltose in Anemia, Iron-Deficiency that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06061393Western Galilee Hospital-NahariyaComparison Between Outcomes of Pregnant Women Treated With Ferinject vs. Venofer for Iron Deficiency Anemia | 2027-09 |
| NCT07772453Zhaojian Niu,MDFerric Carboxymaltose Versus Iron Sucrose for Iron Deficiency Anemia After Radical Gastrectomy for Gastric Cancer | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this project is to assess the feasibility, clinical effectiveness, and cost-effectiveness of IV iron therapy using ferric carboxymaltose (FCM) as a treatment for pediatric patients with iron deficiency anemia (IDA) in the emergency department (ED).
The primary objectives are to:
A secondary objective of this study is to evaluate if additional laboratory markers such as soluble transferrin receptor (sTfR) or reticulocyte hemoglobin equivalent can serve as potential surrogate markers for diagnosing and monitoring treatment response of IDA between oral iron and IV FCM.
By evaluating clinical outcomes such as the time to resolution of anemia, hospitalization rates and need for PRBC transfusion, assessing the feasibility of FCM implementation, and secondarily exploring potential adjunct markers for monitoring IDA, this study aims to fill the current research gap and potentially revolutionize management of IDA in pediatric emergency care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive oral iron supplementation
Drug: Ferrous Sulfate
Participants are randomized to receive oral iron supplementation or IV Ferric carboxymaltose
Drug: Ferric Carboxymaltose (FCM)
Participants with recurrent or refractory iron deficiency anemia will be randomized to receive oral iron supplementation or IV Ferric carboxymaltose
Also known as: injectafer
Newly diagnosed iron deficiency anemia participants will receive oral iron supplementation
Also known as: fer-in-sol, slow Fe
Time to resolution of anemia
days to normalization of Hgb with treatment
Time frame: 6 months
Need for blood transfusions
Volume of blood transfused
Time frame: 6 months
Rates of Hospitalizations
Number of patients with iron deficiency anemia enrolled on study and hospitalized due to their anemia
Time frame: 6 months
Re-presentation rates
The number of patients enrolled on the study that re-present to the ED for ongoing care of their anemia
Time frame: 6 months
Time spent in the Emergency department
Length of stay measured, in hours, in the emergency department.
Time frame: 6 months
Adverse reaction to interventional treatment
Side effects of treatment with iron
Time frame: 6 months
Treatment tolerability
Adherence to oral iron therapy
Time frame: 6 months
Changes in laboratory biomarkers
Associated changes in soluble transferrin receptor and reticulocyte hemoglobin equivalent during treatment for iron deficiency anemia
Time frame: 6 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2026; primary completion for Jun 2026, 4 months later.
Of 43 non-industry phase 4 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 35. This study's planned 4 months is below that.
Counting every sponsor, half of 51 studies reached it within 22 months; a quarter within 15 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferric carboxymaltose
Children's Hospital of Orange County